Irinotecan (also known as CPT-11) is a topoisomerase I inhibitor first approved for clinical
use as an anticancer agent in 1996. Over the past more than two decades, it has been …

After the rapid development of new classes of antineoplastic drugs, research activities have
focused their efforts to the identification of predictive markers of drug activity and tolerability …

IRINOTECAN IS unique among the camptothecins be-cause of its propensity to cause
diarrhea, often of greater severity and clinical impact than its other major toxicity …

Abstract Irinotecan (CPT-11), a first-line chemotherapy for advanced colorectal cancer,
causes serious diarrhea in patients receiving treatment. The underlying mechanism has …

Irinotecan (CPT-11, 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin) has
exhibited clinical activities against a broad spectrum of carcinomas by inhibiting DNA …

Irinotecan, a camptothecin analogue, is a prodrug which requires bioactivation to form the
active metabolite SN-38. SN-38 acts as a DNA topoisomerase I poison. Irinotecan has been …

Background. Irinotecan is a selective inhibitor of topoisomerase I, an enzyme part of the
replication and transcription system of DNA. Irinotecan is employed, with different modalities …

Objective. Delayed-type diarrhea is a common side effect of irinotecan and is associated
with a bacterial-mediated formation of the active irinotecan metabolite SN-38 from its …

Irinotecan (CPT-11) is a widely used anticancer drug, especially for the treatment of
colorectal cancer. Irinotecan is considered an inactive prodrug that requires activation to the …

Irinotecan-induced severe diarrhea (IISD) not only limits irinotecan's application but also
significantly affects patients' quality of life. However, existing animal models often …